InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...
Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target ...
The Cool Down on MSN4d
Healthcare company keeps over 450,000 pounds of harmful waste out of landfills — here's how"My patients appreciate being able to recycle their used eye health materials." Healthcare company keeps over 450,000 pounds ...
InflammX Therapeutics, Inc. has entered into an option agreement granting Bausch + Lomb the right to acquire the company. InflammX’s pipeline includes an orally dosed therapeutic candidate targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback